Tim-3 finds its place in the cancer immunotherapy landscape

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

(2020) Uma Borate et al.   BLOOD

Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T Cells

(2019) Sema Kurtulus et al.   IMMUNITY

Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy

(2019) Imran Siddiqui et al.   IMMUNITY

1202PPhase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy

(2019) N Mach et al.   ANNALS OF ONCOLOGY

TIM-3 Regulates CD103 + Dendritic Cell Function and Response to Chemotherapy in Breast Cancer

(2018) Álvaro de Mingo Pulido et al.   CANCER CELL

The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions

(2018) Tong Zhang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC

(2018) Jie Ji et al.   Cell Death & Disease

Abstract 3825: INCAGN02390, a novel antagonist antibody that targets the co-inhibitory receptor TIM-3

(2018) Jeremy Waight et al.   CANCER RESEARCH

Abstract 5629: Preclinical characterization of Sym023 a human anti-TIM3 antibody with a novel mechanism of action

(2018) Trine Lindsted et al.   CANCER RESEARCH

Induction and transcriptional regulation of the co-inhibitory gene module in T cells

(2018) Norio Chihara et al.   NATURE

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

(2018) Moshe Sade-Feldman et al.   CELL

Engineering therapeutic bispecific antibodies using CrossMab technology

(2018) Christian Klein et al.   METHODS

Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome

(2018) Tenzin Gayden et al.   NATURE GENETICS

High resolution X-ray and NMR structural study of human T-cell immunoglobulin and mucin domain containing protein-3

(2018) Amit K. Gandhi et al.   Scientific Reports

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

(2018)   Journal for ImmunoTherapy of Cancer

TIM-3 is a potential prognostic marker for patients with solid tumors: A systematic review and meta-analysis

(2017) Yang Zhang et al.   Oncotarget

Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes

(2017) Toshio Asayama et al.   Oncotarget

Identification of pharmacological agents that induce HMGB1 release

(2017) Peng Liu et al.   Scientific Reports

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy

(2017) Catherine A. Sabatos-Peyton et al.   OncoImmunology

PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma

(2017) Kostandinos Sideras et al.   OncoImmunology

32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One

(2017)   Journal for ImmunoTherapy of Cancer

The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells

(2017) Isabel Gonçalves Silva et al.   EBioMedicine

Critical Role for CD103 + /CD141 + Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma

(2016) Edward W. Roberts et al.   CANCER CELL

HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins

(2016) Damien Bertheloot et al.   Cellular & Molecular Immunology

Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody

(2016) A. Murtaza et al.   EUROPEAN JOURNAL OF CANCER

Interleukin-35 Limits Anti-Tumor Immunity

(2016) Meghan E. Turnis et al.   IMMUNITY

Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells

(2016) Jiyi Xia et al.   Molecular Medicine Reports

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy

(2016) Se Jin Im et al.   NATURE

Reduced Expression of Galectin-9 Contributes to a Poor Outcome in Colon Cancer by Inhibiting NK Cell Chemotaxis Partially through the Rho/ROCK1 Signaling Pathway

(2016) Yang Wang et al.   PLoS One

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Polymorphisms in TIM-3 and breast cancer susceptibility in Chinese women: A case-control study

(2016) Zheng Wang et al.   Oncotarget

Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer

(2016) Gulidanna Shayan et al.   OncoImmunology

Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis

(2016) Xingwei Jiang et al.   OncoImmunology

A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression

(2015) Yoshikane Kikushige et al.   Cell Stem Cell

Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma

(2015) Liyun Xu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo

(2015) KOJI FUJITA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Galectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinoma

(2015) Hangcheng Fu et al.   TUMOR BIOLOGY

Association between polymorphisms in the promoter region of T cell immunoglobulin and mucin domain-3 and myasthenia gravis-associated thymoma

(2015) GUOWU XU et al.   Oncology Letters

An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction

(2015) Chen Zhu et al.   Nature Communications

Variation in human cancer cell external phosphatidylserine is regulated by flippase activity and intracellular calcium

(2015) Subrahmanya D. Vallabhapurapu et al.   Oncotarget

The Coordinated Actions of TIM-3 on Cancer and Myeloid Cells in the Regulation of Tumorigenicity and Clinical Prognosis in Clear Cell Renal Cell Carcinomas

(2015) Y. Komohara et al.   Cancer Immunology Research

Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity

(2014) Miranda L. Broz et al.   CANCER CELL

Immunoregulation of Dendritic Cells by the Receptor T cell Ig and Mucin Protein-3 via Bruton’s Tyrosine Kinase and c-Src

(2014) Neeraj Maurya et al.   JOURNAL OF IMMUNOLOGY

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion

(2014) Yu-Hwa Huang et al.   NATURE

Galectin Expression Profiling Identifies Galectin-1 and Galectin-9Δ5 as Prognostic Factors in Stage I/II Non-Small Cell Lung Cancer

(2014) Iris A. Schulkens et al.   PLoS One

Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade

(2014) I. P. da Silva et al.   Cancer Immunology Research

T Cell Ig and Mucin Domain-Containing Protein 3 Is Recruited to the Immune Synapse, Disrupts Stable Synapse Formation, and Associates with Receptor Phosphatases

(2013) K. L. Clayton et al.   JOURNAL OF IMMUNOLOGY

Tim-3 Expression in Cervical Cancer Promotes Tumor Metastasis

(2013) Yang Cao et al.   PLoS One

Tim-3 Expression Defines Regulatory T Cells in Human Tumors

(2013) Jing Yan et al.   PLoS One

Decreased Galectin-9 and Increased Tim-3 Expression Are Related to Poor Prognosis in Gastric Cancer

(2013) Jing Jiang et al.   PLoS One

TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer

(2013) Kaori Sakuishi et al.   OncoImmunology

Galectin-9 Acts as a Prognostic Factor with Antimetastatic Potential in Hepatocellular Carcinoma

(2012) Zhao-Yang Zhang et al.   Asian Pacific Journal of Cancer Prevention

Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma

(2012) Hang Li et al.   HEPATOLOGY

Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

(2012) Shigeki Chiba et al.   NATURE IMMUNOLOGY

Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion

(2012) Manu Rangachari et al.   NATURE MEDICINE

TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression

(2012) Xin Gao et al.   PLoS One

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

(2011) Q. Zhou et al.   BLOOD

Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors

(2011) S. F. Ngiow et al.   CANCER RESEARCH

TIM polymorphisms—genetics and function

(2011) J Lee et al.   GENES AND IMMUNITY

Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling Pathways

(2011) J. Lee et al.   MOLECULAR AND CELLULAR BIOLOGY

Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker

(2011) M. Jan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells

(2010) Yoshikane Kikushige et al.   Cell Stem Cell

T-bet, a Th1 transcription factor regulates the expression of Tim-3

(2010) Ana C. Anderson et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients

(2010) Julien Fourcade et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells

(2010) V. Dardalhon et al.   JOURNAL OF IMMUNOLOGY

Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection

(2010) H.-T. Jin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CEACAM1+ myeloid cells control angiogenesis in inflammation

(2009) A. K. Horst et al.   BLOOD

Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation

(2009) M. Nakayama et al.   BLOOD

Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner

(2009) Luize G. Lima et al.   CANCER LETTERS

Galectin-9 Is a High Affinity IgE-binding Lectin with Anti-allergic Effect by Blocking IgE-Antigen Complex Formation

(2009) Toshiro Niki et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

(2009) Luca Gattinoni et al.   NATURE MEDICINE

Immunogenic death of colon cancer cells treated with oxaliplatin

(2009) A Tesniere et al.   ONCOGENE

HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression

(2009) James F Curtin et al.   PLOS MEDICINE

Structural analysis of the recognition mechanism of poly-N-acetyllactosamine by the human galectin-9 N-terminal carbohydrate recognition domain

(2008) M. Nagae et al.   GLYCOBIOLOGY